Stay updated on Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.

Latest updates to the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page
- Check6 days agoChange DetectedAdded Melanoma as a related topic and MedlinePlus Genetics as related topics on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded a new site revision entry: Revision: v3.3.2. Removed the Melanoma topic and the related MedlinePlus Genetics topic, as well as the older Revision: v3.2.0.SummaryDifference0.2%

- Check27 days agoChange DetectedRemoval of the government funding/operating status banner from the bottom of the page. This change does not affect the study details, eligibility criteria, or results; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check49 days agoChange DetectedA MedlinePlus Genetics related topic for Melanoma has been added to the page. This is a minor informational enhancement that does not affect study details or user workflows.SummaryDifference0.9%

- Check63 days agoChange DetectedRemoved a MedlinePlus Genetics topic: Melanoma.SummaryDifference0.2%

- Check70 days agoChange DetectedUpdate: Version bumped to v3.2.0 and a new government funding operating-status notice added; previous v3.1.0 revision removed.SummaryDifference3%

Stay in the know with updates to Nivolumab + HF10 for Resectable Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab + HF10 for Resectable Melanoma Clinical Trial page.